Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate

British Journal of Rheumatology

Volumn 37, Issue 11, 1998, Pages 1220-1226

  Rau, R ^a,c   Herborn, G ^a   Menninger, H ^a   Sangha, O ^b  

^a Asklepios Klinikum Bad Abbach   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Rheumaklinik   (Germany)

Author keywords

Clinical trials; Gold sodium thiomalate; Methotrexate; Radiology; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; C REACTIVE PROTEIN; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GOLD SODIUM THIOMALATE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031787944     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum 1989;32:221-9.
2. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36: 729-40.
3. Williams HJ, Willkens RF, Samuelson CO Jr et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985;28:721-30.
4. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
5. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomised, double-blind study. Ann Intern Med 1985; 103:489-96.
6. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in longterm therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
7. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992;35:138-45.
8. Weinblatt ME, Trentham DE, Fraser PA et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167-75.
9. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994; 37:1492-8.
10. Weinblatt ME, Polisson R, Blotner SD et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomised trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-9.
11. Sany J, Anaya JM, Lussiez V, Couret M, Combe B. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol 1991;18:1323-7.
12. Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989;28:147-53.
13. Alarcon GS, Lopez-Mendez A, Walter J et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. [See comments] J Rheumatol 1992; 19:1868-73.
14. Weinblatt ME, Weissman BN, Holdsworth DE et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992;35:129-37.
15. Reykdal S, Steinsson K, Sigurjonsson K, Brekkan A. Methotrexate treatment of rheumatoid arthritis: effects on radiological progression. Scand J Rheumatol 1989; 18:221-6.
16. Drosos AA, Karantanas AH, Psychos D, Tsampoulas C, Moutsopoulos HM. Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin Rheumatol 1990;9:342-5.
17. Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med 1974;80:21-6.
18. Larsen A, Horton J, Howland C. The effects of auranofin and parenteral gold in the treatment of rheumatoid arthritis: an X-ray analysis. Clin Rheumatol 1984; 3(suppl. 1):97-104.
19. Cats A. A multicentre controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosage. Agents Actions 1976;6:355-63.
20. Anonymous. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973;16:353-8.
21. Buckland-Wright JC, Clarke GS, Walker SR. Erosion number and area progression in the wrists and hands of rheumatoid patients: a quantitative microfocal radiographic study. Ann Rheum Dis 1989;48:25-9.
22. Sharp JT, Lidsky MD, Duffy J. Clinical responses during gold therapy for rheumatoid arthritis. Changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis Rheum 1982;25:540-9.
23. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
24. Morassut P, Goldstein R, Cyr M, Karsh J, McKendry RJ. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis -a randomised, double blind 26-week trial. J Rheumatol 1989;16:302-6.
25. Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double blind randomised parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol 1991;18:328-33.
26. Suarez-Almazor ME, Fitzgerald A, Grace M, Russell AS. A randomised controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis. J Rheumatol 1988;15:753-6.
27. Bywaters EGL, Dresner E. The prognosis in rheumatoid arthritis. Q J Med 1952;21:463.
28. Fleming A, Crown JM, Corbett M. The relationship of early features to prognosis in rheumatoid disease. Scand J Rheumatol 1975;suppl. 8:Abstract 32.
29. Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976;35:357-60.
30. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995;95:2120-6.
31. Rau R, Herborn G, Menninger H et al. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997;36:345-52.
32. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
33. Raspe HH, Kindel P, Vesterling K, Kohlmann T. Change in functional capacity and pain intensity of 81 RA patients treated with Azulfidine RA or aurothioglucose. Preliminary statistical assessment of the German multicenter study of the treatment of chronic polyarthritis with Azulfidine RA. Z Rheumatol 1987; 46:71-5.
34. Rau R, Wassenberg S, Herborn G, Stucki G. A new method of scoring radiographic change in rheumatoid arthritis. J Rheumatol 1998; in press.
35. Sharp JT, Wolfe F, Corbett M et al. Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification? Ann Rheum Dis 1993;52:332-7.
36. Möttönen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-53.
37. Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977;1:195-7.
38. Fries JF, Bloch DA, Sharp JT et al. Assessment of radiologie progression in rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 1986;29:1-9.
39. Thompson PW, Silman AJ, Kirwan JR, Currey HL. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum 1987;30:618-23.
40. Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982;9:224-8.
41. Walsh L, Davies P, McConkey B. Relationship between erythrocyte sedimentation rate and serum C-reactive protein in rheumatoid arthritis. Ann Rheum Dis 1979;38:362-3.
42. Cats A, Hazevoet HM. Significance of positive tests for rheumatoid factor in the prognosis of rheumatoid arthritis. A follow-up study. Ann Rheum Dis 1970;29: 254-60.
43. Masi AT, Maldonado-Cocco JA, Kaplan SB, Feigenbaum SL, Chandler RW. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum 1976;4:299-326.
44. Wawrzynska-Pagowska J, Brzezinska B, Brzozowska M et al. Observations on the symptoms and signs of 'early' rheumatoid arthritis in a prospective study. Acta Rheumatol Scand 1970;16:99-105.
45. Arnason JA, Jonsson T, Brekkan A, Sigurjonsson K, Valdimarsson H. Relation between bone erosions and rheumatoid factor isotypes. Ann Rheum Dis 1987; 46:380-4.
46. Dawes PT, Fowler PD, Jackson R et al. Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy. Ann Rheum Dis 1986;45:945-9.
47. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973;2:96-100.
48. Tugwell P, Boers M. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol 1993;20:528-30.
49. Pincus T. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992;21(suppl. 3):2-15.
50. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15(suppl. 17):S27-38.